Evidence map›Paper›PMID 23410564›Full record

Trial reportThe American journal of medicine2013

The long-term effectiveness of a lifestyle intervention in severely obese individuals.

Jessica L Unick, Daniel Beavers, Dale S Bond, Jeanne M Clark, John M Jakicic, Abbas E Kitabchi, William C Knowler, Thomas A Wadden, Lynne E Wagenknecht, Rena R Wing and 1 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 124 citations in OpenAlex.

  1. Does lifestyle intervention lower clinically significant cognitive impairment risk?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Cost-Effectiveness of Personalised Nutrition in Adults With Overweight and Obesity: PREVENTOMICS Studies in Poland and the UK.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025
    Trial
  3. A randomized controlled trial to reduce post-cessation weight gain.International journal of obesity (2005) · 2023
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Jessica L UnickWeight Control and Diabetes Research Center, The Miriam Hospital and Warren Alpert Medical School at Brown University, Providence, RI 02903, USA. junick@lifespan.org
Daniel Beavers
Dale S Bond
Jeanne M Clark
John M Jakicic
Abbas E Kitabchi
William C Knowler
Thomas A Wadden
Lynne E Wagenknecht
Rena R Wing
Look AHEAD Research Group
Brown University · USWake Forest University · USJohns Hopkins University · USMiriam Hospital · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Pennsylvania · USUniversity of Pittsburgh · USUniversity of Tennessee Health Science Center · US

Funding

UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
Look AHEAD: Action for Health in DiabetesU01DK057136 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 1999 to 2020
$54.9M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI WALDERS, NATALIE · 1985 to 2008
$52.6M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Julie Mathieu · 1986 to 2026
$41.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI HOGE, ELIZABETH A · 1985 to 2008
$37.4M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BRYAN C BERGMAN · 1995 to 2026
$32.6M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PLISZKA, STEVEN R. · 1985 to 2008
$23.1M
SHOW PROJECTU01DK057154 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1999 to 2020
$23.1M
Look AHEAD: Action for Health DiabetesU01DK057178 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1999 to 2020
$21.2M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI EARLEY, CHRISTOPHER J · 1986 to 2007
$20.2M
Intramural NIH HHSNCATS NIH HHS UL1 TR000005NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01RR000056NCRR NIH HHS M01RR00051NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01RR0021140NCRR NIH HHS M01 RR002719NCRR NIH HHS M01RR01066NCRR NIH HHS M01RR01346NCRR NIH HHS M01RR02719NCRR NIH HHS UL1 RR 024153NCRR NIH HHS UL1 RR024153NIDDK NIH HHS DK 046204NIDDK NIH HHS DK56990NIDDK NIH HHS DK56992NIDDK NIH HHS DK57002NIDDK NIH HHS DK57008NIDDK NIH HHS DK57078NIDDK NIH HHS DK57131NIDDK NIH HHS DK57135NIDDK NIH HHS DK57136NIDDK NIH HHS DK57149NIDDK NIH HHS DK57151NIDDK NIH HHS DK57154NIDDK NIH HHS DK57171NIDDK NIH HHS DK57177NIDDK NIH HHS DK57178NIDDK NIH HHS DK57182NIDDK NIH HHS DK57219NIDDK NIH HHS K01 DK083438NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK079637NIDDK NIH HHS P30 DK48520NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219NIMHD NIH HHS P20 MD006899
6 · The paper itself

Abstract

objectiveSevere obesity (body mass index [BMI] ≥40 kg/m(2)) is a serious public health concern. Although bariatric surgery is an efficacious treatment approach, it is limited in reach; thus, nonsurgical treatment alternatives are needed. We examined the 4-year effects of an intensive lifestyle intervention on body weight and cardiovascular disease risk factors among severely obese, compared with overweight (25 ≤BMI <30), class I (30 ≤BMI <35), and class II obese (35 ≤BMI <40) participants.

methodsThere were 5145 individuals with type 2 diabetes (45-76 years, BMI ≥25 kg/m(2)) randomized to an intensive lifestyle intervention or diabetes support and education. The lifestyle intervention group received a behavioral weight loss program that included group and individual meetings, a ≥10% weight loss goal, calorie restriction, and increased physical activity. Diabetes support and education received a less intense educational intervention. Four-year changes in body weight and cardiovascular disease risk factors were assessed.

resultsAcross BMI categories, 4-year changes in body weight were significantly greater in lifestyle participants compared with diabetes support and education (Ps <.05). At year 4, severely obese lifestyle participants lost 4.9%±8.5%, which was similar to class I (4.8%±7.2%) and class II obese participants (4.4%±7.6%), and significantly greater than overweight participants (3.4%±7.0%; P <.05). Four-year changes in low-density-lipoprotein cholesterol, triglycerides, diastolic blood pressure, HbA(1c), and blood glucose were similar across BMI categories in lifestyle participants; however, the severely obese had less favorable improvements in high-density-lipoprotein cholesterol (3.1±0.4 mg/dL) and systolic blood pressure (-1.4±0.7 mm Hg) compared with the less obese (Ps <.05).

conclusionLifestyle interventions can result in important long-term weight losses and improvements in cardiovascular disease risk factors among a significant proportion of severely obese individuals.

Indexed as

Risk Reduction BehaviorAgedBlood GlucoseBlood PressureBody Mass IndexCholesterol, LDLCombined Modality TherapyDiabetes Mellitus, Type 2Diet, ReducingExercise TherapyFemaleHumansMaleMiddle AgedObesityTreatment OutcomeBlood GlucoseCholesterol, LDLTriglycerides

Identifiers

PMID23410564
PMCPMC3574274
OpenAlexW2136979308

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.